A neurologist's personal battle against Alzheimer's disease
Ever since Dr. Allen Roses and his group at Duke reported in the 1990s that people carrying the APOE-4 gene are at greater risk for getting Alzheimer’s, there has been uncertainty about how a gene that...
Abnormal tau protein is found in the neurofibrillary tangles found in nerve cells in the brain starting a few years before the onset of cognitive impairment in Alzheimer’s disease. Most drug trials attempting to...
Increasing evidence has shown that getting too little sleep increases the risk of developing dementia. In one recent study those routinely getting 6 or less hours of sleep had a significantly greater chance of developing...
In 1999 my friend John and I took a week-long sailing course to qualify for bareboat chartering, renting a boat without hired captain and crew. The course took place in the waters of the...
Now that Aduhelm (aducanumab) has been approved by the FDA for people with early-stage Alzheimer’s, those with mild cognitive impairment or mild dementia, who will be responsible for the $56,000 annual price tag? A...
A few days ago, my friend John Harland and I motored through the Columbia River Gorge on my mini tug, Lizzie G. In the Pacific Northwest and perhaps elsewhere there used to be a tradition...
A recurring theme of my blog has been that our best shot at attacking Alzheimer’s disease is in the earliest stage, before cognitive impairment has started. We now know that the first pathological signs...
Yesterday I came across an interesting paper from 2013 in Lancet Neurology that adds important information about the case of Auguste D, the first patient diagnosed with what was later called Alzheimer’s disease. I mentioned this...
As reported in the New York Times today, two prominent American medical institutions, the Cleveland Clinic and the Mt. Sinai Health System in New York, have announced that they will not allow administration of...
Today Biogen announced the changes highlighted in yellow below in the prescribing information for Aduhelm, recently approved for treatment of Alzheimer’s disease. There were several problems with the FDA’s initial brand label authorizing use...
Recent Comments